LEPRA2 reduced VEGF secretion and expression in 4T1 murine breast cancer cells, and treatment with LEPRA2 significantly reduced VEGF levels in serum, as well as tumor growth in 4T1 implant tumors (85). Here, VEGFA is linked to breast carcinoma.